Apex Venture Advisors (AVA) is the parent firm of AVA Investment Analytics focused on the private markets.
You can find out more information about AVA by visiting our website www.apexva.com or click here to stay on this site and open up a new screen.
Mike Stathis serves as the Managing Principal of Apex Venture Advisors (AVA), a business and investment intelligence firm consulting venture firms, corporations and hedge funds. AVA consists of three units: a private markets division, a public markets division and a publishing company. Mike’s work in the private markets includes valuation analysis, deal structuring, and business strategy, with a technology focus in biopharmaceuticals, healthcare IT and telemedicine.
In the public markets Mike assists hedge funds, endowments and financial firms as the Chief Investment Strategist of AVA Investment Analytics. He provides clients with proprietary investment strategies, valuation analysis, market forecasting, risk management and distressed securities analysis.
As the only investment expert who predicted the financial apocalypse in detail, as documented in the 2006 release of America’s Financial Apocalypse and the 2007 release of Cashing in on the Real Estate Bubble, Mike has been particularly active helping investors navigate the real estate and banking crisis. The accuracy of his predictions has positioned him as one of America’s most insightful and creative financial experts. His first book, The Startup Company Bible for Entrepreneurs has been used in business schools as a required text for completion of the MBA program.
Prior to Apex Advisors, Mike worked at UBS and Bear Stearns, focusing on asset management and merchant banking. He holds a Masters of Science in biological chemistry and biophysics from the University of Pennsylvania and was formerly a National Science Foundation research fellow at U.C. Berkeley.
Mike has previously provided his expertise to several corporations, hedge funds and venture capital firms. He has carved out business strategies and written business plans for Fortune 500 corporations and venture fund investments. He has provided private and public company valuation and securities analysis to fund managers, venture capital and private equity investors. He has even been consulted by hedge funds seeking to better understand the science and intellectual property challenges found in the biopharmaceuticals industry.